Abstract
Phase Ib Study Design Evaluating The Safety, Pharmacokinetics And Pharmacodynamics Of Selnoflast, A Novel NLRP3 Inflammasome Inhibitor In Early-Stage PD (P2-11.007)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
